세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 보고서(2025년)

Heterozygous Familial Hypercholesterolemia Management Global Market Report 2025

US $ 4,490 ￦ 6,319,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,134,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,949,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이형접합 가족성 고콜레스테롤혈증 관리 시장 규모는 향후 몇 년 동안 급성장할 것으로 예상됩니다. 예측 기간 동안의 성장은 원격 의료 서비스의 확대, 만성 질환의 유병률 증가, 임상 시험의 증가, 노인 인구의 증가, 약물 파이프라인 개발의 급증에 기인할 수 있습니다. 예측 기간의 주요 트렌드에는 디지털 건강 솔루션의 통합, 치료 옵션의 발전, 병용 치료의 개발, 기술 혁신 및 새로운 치료법의 출현이 포함됩니다.

심혈관 질환의 유병률 증가는 이형접합 가족성 고콜레스테롤혈증 관리 시장의 확대를 견인할 것으로 예상됩니다. 심혈관 질환(CVD)은 관상동맥 질환, 심부전, 뇌졸중 등 심장과 혈관에 영향을 미치는 다양한 질환을 포괄합니다. 전 세계적으로 심혈관 질환의 발병률이 증가하는 것은 건강에 해로운 식습관, 앉아서 생활하는 생활 방식, 비만, 인구 고령화 등의 위험 요인 증가와 관련이 있습니다. 이형접합 가족성 고콜레스테롤혈증을 효과적으로 관리하는 것은 죽상경화증 및 심장 관련 합병증의 주요 위험 요인인 높은 콜레스테롤 수치를 조절하여 심혈관 질환을 예방하는 데 매우 중요한 역할을 합니다. 예를 들어, 미국 정부 기관인 질병통제예방센터(CDC)에 따르면 2022년에 미국에서 약 80만 5,000명이 심장마비를 겪었으며, 그 중 60만 5,000명이 첫 발례, 20만명이 심장 발작의 기왕력이 있는 사람에게 발병한다고 합니다. 결과적으로 심혈관 질환 유병률의 증가는 이형접합 가족성 고콜레스테롤혈증 관리 시장의 성장에 박차를 가하고 있습니다.

이형접합 가족성 고콜레스테롤혈증 관리 시장의 선도 기업들은 지질 대사를 개선하고 콜레스테롤 수치를 낮추기 위해 안지오포이에틴 기반 치료과 같은 혁신적인 치료법을 개발하는 데 주력하고 있습니다. 안지오포이에틴은 혈관 형성(혈관 신생)을 조절하고 혈관 안정성을 유지하는 단백질 계열의 물질입니다. 예를 들어, 2023년 3월 미국 생명공학 회사인 리제네론 파마슈티컬스는 미국 식품의약국(FDA)으로부터 동형접합 가족성 고콜레스테롤혈증(HoFH)이 있는 5-11세 어린이를 위한 에브키자(에비나쿠맙-dgnb)를 승인받았습니다. 이 최초의 단일 클론 항체는 지질 대사를 방해하는 단백질인 ANGPTL3를 억제하여 저밀도 지단백(LDL) 콜레스테롤과 트리글리세리드 수치를 낮추는 방식으로 작용합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 성장률 분석
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 스타틴
• 에제티미브
• PCSK9 억제제
• 로미타피드
• 미포메르센
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 주사제
• 정맥 내
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 환자의 인구 통계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 어린이
• 성인
• 노인
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 의료 센터
• 클리닉
• 기타 용도
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 스타틴 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 아토르바스타틴
• 심바스타틴
• 로스바스타틴
• 프라바스타틴
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 에제티미브 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 에제티미브(단일치료)
• 에제티미브 병용 치료(스타틴 병용)
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : PCSK9 억제제 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 아리로쿠맙
• 에볼로쿠맙
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 로미타피드 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 로미타피드(단일치료)
• 로미타피드 병용 치료
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 미포메르센 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 미포메르센(단일치료)
• 미포메르센 병용 치료

제7장 지역별 및 국가별 분석

• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 경쟁 구도
• 이형접합 가족성 고콜레스테롤혈증 관리 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Johnson & Johnson 개요, 제품 및 서비스, 전략 및 재무 분석
  • Roche Holding AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Sanofi SA
• Bristol-Myers Squibb
• AstraZeneca plc
• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Gilead Sciences Inc.
• Amgen Inc.
• Merck KGaA
• Regeneron Pharmaceuticals Inc.
• Ipsen SA
• Chiesi Farmaceutici SpA
• Ferring Pharmaceuticals Limited
• Esperion Therapeutics Inc.
• Aegerion Pharmaceuticals Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 이형접합 가족성 고콜레스테롤혈증 관리 시장(2029년) : 새로운 기회를 제공하는 국가
• 이형접합 가족성 고콜레스테롤혈증 관리 시장(2029년) : 새로운 기회를 제공하는 부문
• 이형접합 가족성 고콜레스테롤혈증 관리 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Heterozygous familial hypercholesterolemia (HeFH) management is a comprehensive strategy aimed at controlling elevated low-density lipoprotein cholesterol (LDL-C) levels in individuals with a genetic predisposition to high cholesterol. The goal is to lower the risk of premature cardiovascular disease (CVD) through lifestyle modifications, lipid-lowering medications, and, in certain cases, advanced treatments such as lipoprotein apheresis.

The primary treatment options for HeFH management include statins, ezetimibe, PCSK9 inhibitors, lomitapide, and mipomersen. Statins are a class of medications that lower cholesterol levels by inhibiting HMG-CoA reductase, a key enzyme in cholesterol production in the liver. The available routes of administration include oral, injectable, and intravenous. The treatment applies to various patient demographics, including children, adults, and the elderly, and is utilized in multiple healthcare settings such as hospitals, medical centers, clinics, and others.

The heterozygous familial hypercholesterolemia management market research report is one of a series of new reports from The Business Research Company that provides heterozygous familial hypercholesterolemia management market statistics, including the heterozygous familial hypercholesterolemia management industry global market size, regional shares, competitors with the heterozygous familial hypercholesterolemia management market share, detailed heterozygous familial hypercholesterolemia management market segments, market trends, and opportunities, and any further data you may need to thrive in the heterozygous familial hypercholesterolemia management industry. This heterozygous familial hypercholesterolemia management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The heterozygous familial hypercholesterolemia management market size has grown rapidly in recent years. It will grow from $10.84 billion in 2024 to $12.07 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth during the historic period can be attributed to the increasing prevalence of cardiovascular diseases, government initiatives, rising investment in research and development activities, greater awareness and diagnosis of HeFH, and the growing demand for personalized therapies.

The heterozygous familial hypercholesterolemia management market size is expected to see rapid growth in the next few years. It will grow to $18.37 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth during the forecast period can be attributed to the expansion of telehealth services, the rising prevalence of chronic illnesses, the increasing number of clinical trials, the growing geriatric population, and the surge in drug pipeline developments. Key trends in the forecast period include the integration of digital health solutions, advancements in therapeutic options, the development of combination therapies, technological innovations, and the emergence of novel treatments.

The increasing prevalence of cardiovascular diseases is expected to drive the expansion of the heterozygous familial hypercholesterolemia management market. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The growing incidence of CVDs worldwide is linked to rising risk factors such as unhealthy diets, sedentary lifestyles, obesity, and an aging population. Effective management of heterozygous familial hypercholesterolemia plays a vital role in preventing cardiovascular diseases by controlling high cholesterol levels, a major risk factor for atherosclerosis and heart-related complications. For example, according to the Centers for Disease Control and Prevention (CDC), a US-based government agency, approximately 805,000 people in the United States suffered a heart attack in 2022, with 605,000 being first-time cases and 200,000 occurring in individuals with a previous history of heart attacks. As a result, the rising prevalence of cardiovascular diseases is fueling the growth of the heterozygous familial hypercholesterolemia management market.

Leading companies in the heterozygous familial hypercholesterolemia management market are focusing on developing innovative treatments, such as angiopoietin-based therapies, to improve lipid metabolism and lower cholesterol levels. Angiopoietins are a family of proteins that regulate blood vessel formation (angiogenesis) and maintain vascular stability. For instance, in March 2023, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, received approval from the U.S. Food and Drug Administration (FDA) for Evkeeza (evinacumab-dgnb) for children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). This first-in-class monoclonal antibody works by inhibiting ANGPTL3, a protein that disrupts lipid metabolism, thereby reducing low-density lipoprotein (LDL) cholesterol and triglyceride levels. This approval provides a novel therapeutic option for pediatric patients with limited treatment alternatives and a high risk of cardiovascular events.

In February 2025, Tempus AI Inc., a US-based testing laboratory company, acquired Ambry Genetics for an undisclosed amount. This acquisition aims to enhance diagnostics and patient care by integrating artificial intelligence with genetic testing and expanding into new disease areas. Ambry Genetics Corporation, a US-based company, specializes in genetic testing for heterozygous familial hypercholesterolemia (HeFH).

Major players in the heterozygous familial hypercholesterolemia management market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Merck KGaA, Regeneron Pharmaceuticals Inc., Ipsen S.A., Chiesi Farmaceutici S.p.A., Ferring Pharmaceuticals Limited, Esperion Therapeutics Inc., Aegerion Pharmaceuticals Inc., Verve Therapeutics Inc.

North America was the largest region in the heterozygous familial hypercholesterolemia management market in 2024. The regions covered in heterozygous familial hypercholesterolemia management report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the heterozygous familial hypercholesterolemia management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The heterozygous familial hypercholesterolemia management market includes revenues earned by entities by providing services such as genetic testing and diagnosis, cholesterol monitoring, and lifestyle counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Heterozygous Familial Hypercholesterolemia Management Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on heterozygous familial hypercholesterolemia management market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for heterozygous familial hypercholesterolemia management ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The heterozygous familial hypercholesterolemia management market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Statins; Ezetimibe; PCSK9 Inhibitors; Lomitapide; Mipomersen
• 2) By Route Of Administration: Oral; Injectable; Intravenous
• 3) By Patient Demographics: Children; Adults; Elderly
• 4) By Application: Hospitals; Medical Centers; Clinics; Other Applications
• Subsegments:
• 1) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin
• 2) By Ezetimibe: Ezetimibe (Monotherapy); Ezetimibe Combination Therapy (With Statins)
• 3) By PCSK9 Inhibitors: Alirocumab; Evolocumab
• 4) By Lomitapide: Lomitapide (Monotherapy); Lomitapide Combination Therapy
• 5) By Mipomersen: Mipomersen (Monotherapy); Mipomersen Combination Therapy
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Heterozygous Familial Hypercholesterolemia Management Market Characteristics

3. Heterozygous Familial Hypercholesterolemia Management Market Trends And Strategies

4. Heterozygous Familial Hypercholesterolemia Management Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Heterozygous Familial Hypercholesterolemia Management Growth Analysis And Strategic Analysis Framework

• 5.1. Global Heterozygous Familial Hypercholesterolemia Management PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Heterozygous Familial Hypercholesterolemia Management Market Growth Rate Analysis
• 5.4. Global Heterozygous Familial Hypercholesterolemia Management Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Heterozygous Familial Hypercholesterolemia Management Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Heterozygous Familial Hypercholesterolemia Management Total Addressable Market (TAM)

6. Heterozygous Familial Hypercholesterolemia Management Market Segmentation

• 6.1. Global Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• Ezetimibe
• PCSK9 Inhibitors
• Lomitapide
• Mipomersen
• 6.2. Global Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• Intravenous
• 6.3. Global Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Children
• Adults
• Elderly
• 6.4. Global Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Medical Centers
• Clinics
• Other Applications
• 6.5. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atorvastatin
• Simvastatin
• Rosuvastatin
• Pravastatin
• 6.6. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of Ezetimibe, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ezetimibe (Monotherapy)
• Ezetimibe Combination Therapy (With Statins)
• 6.7. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of PCSK9 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alirocumab
• Evolocumab
• 6.8. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of Lomitapide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Lomitapide (Monotherapy)
• Lomitapide Combination Therapy
• 6.9. Global Heterozygous Familial Hypercholesterolemia Management Market, Sub-Segmentation Of Mipomersen, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mipomersen (Monotherapy)
• Mipomersen Combination Therapy

7. Heterozygous Familial Hypercholesterolemia Management Market Regional And Country Analysis

• 7.1. Global Heterozygous Familial Hypercholesterolemia Management Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Heterozygous Familial Hypercholesterolemia Management Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market

• 8.1. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Heterozygous Familial Hypercholesterolemia Management Market

• 9.1. China Heterozygous Familial Hypercholesterolemia Management Market Overview
• 9.2. China Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Heterozygous Familial Hypercholesterolemia Management Market

• 10.1. India Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Heterozygous Familial Hypercholesterolemia Management Market

• 11.1. Japan Heterozygous Familial Hypercholesterolemia Management Market Overview
• 11.2. Japan Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Heterozygous Familial Hypercholesterolemia Management Market

• 12.1. Australia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Heterozygous Familial Hypercholesterolemia Management Market

• 13.1. Indonesia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Heterozygous Familial Hypercholesterolemia Management Market

• 14.1. South Korea Heterozygous Familial Hypercholesterolemia Management Market Overview
• 14.2. South Korea Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Heterozygous Familial Hypercholesterolemia Management Market

• 15.1. Western Europe Heterozygous Familial Hypercholesterolemia Management Market Overview
• 15.2. Western Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Heterozygous Familial Hypercholesterolemia Management Market

• 16.1. UK Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Heterozygous Familial Hypercholesterolemia Management Market

• 17.1. Germany Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Heterozygous Familial Hypercholesterolemia Management Market

• 18.1. France Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Heterozygous Familial Hypercholesterolemia Management Market

• 19.1. Italy Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Heterozygous Familial Hypercholesterolemia Management Market

• 20.1. Spain Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market

• 21.1. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market Overview
• 21.2. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Heterozygous Familial Hypercholesterolemia Management Market

• 22.1. Russia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Heterozygous Familial Hypercholesterolemia Management Market

• 23.1. North America Heterozygous Familial Hypercholesterolemia Management Market Overview
• 23.2. North America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Heterozygous Familial Hypercholesterolemia Management Market

• 24.1. USA Heterozygous Familial Hypercholesterolemia Management Market Overview
• 24.2. USA Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Heterozygous Familial Hypercholesterolemia Management Market

• 25.1. Canada Heterozygous Familial Hypercholesterolemia Management Market Overview
• 25.2. Canada Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Heterozygous Familial Hypercholesterolemia Management Market

• 26.1. South America Heterozygous Familial Hypercholesterolemia Management Market Overview
• 26.2. South America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Heterozygous Familial Hypercholesterolemia Management Market

• 27.1. Brazil Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Heterozygous Familial Hypercholesterolemia Management Market

• 28.1. Middle East Heterozygous Familial Hypercholesterolemia Management Market Overview
• 28.2. Middle East Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Heterozygous Familial Hypercholesterolemia Management Market

• 29.1. Africa Heterozygous Familial Hypercholesterolemia Management Market Overview
• 29.2. Africa Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Heterozygous Familial Hypercholesterolemia Management Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Heterozygous Familial Hypercholesterolemia Management Market Competitive Landscape And Company Profiles

• 30.1. Heterozygous Familial Hypercholesterolemia Management Market Competitive Landscape
• 30.2. Heterozygous Familial Hypercholesterolemia Management Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Heterozygous Familial Hypercholesterolemia Management Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb
• 31.3. AstraZeneca plc
• 31.4. Novartis International AG
• 31.5. Takeda Pharmaceutical Company Limited
• 31.6. Eli Lilly and Company
• 31.7. Gilead Sciences Inc.
• 31.8. Amgen Inc.
• 31.9. Merck KGaA
• 31.10. Regeneron Pharmaceuticals Inc.
• 31.11. Ipsen S.A.
• 31.12. Chiesi Farmaceutici S.p.A.
• 31.13. Ferring Pharmaceuticals Limited
• 31.14. Esperion Therapeutics Inc.
• 31.15. Aegerion Pharmaceuticals Inc.

32. Global Heterozygous Familial Hypercholesterolemia Management Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Heterozygous Familial Hypercholesterolemia Management Market

34. Recent Developments In The Heterozygous Familial Hypercholesterolemia Management Market

35. Heterozygous Familial Hypercholesterolemia Management Market High Potential Countries, Segments and Strategies

• 35.1 Heterozygous Familial Hypercholesterolemia Management Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Heterozygous Familial Hypercholesterolemia Management Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Heterozygous Familial Hypercholesterolemia Management Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료